Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation discusses skepticism and diminishing excitement around the hair loss treatment PP405 due to unclear trial results. It also mentions other treatments like finasteride, minoxidil, VDPHL01 (extended-release minoxidil), and GT20026 as potential options for hair loss management.

A user is seeking advice on a new topical hair loss treatment containing Minoxidil 3%, Finasteride 0.3%, Progesterone 1%, Hydrocortisone butyrate 0.1%, and Ketoconazole 0.5%. They are concerned about the systemic absorption of Finasteride and plan to do blood tests and a spermiogram before starting.

The conversation discusses using topical finasteride with propylene glycol, which causes scalp dryness or dandruff. The user also uses Nizoral, Nioxin, and DHT oil, and considers using a scalp conditioner to alleviate dryness.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

Minoxidil, finasteride, and RU58841 are discussed as hair loss treatments. Users express skepticism about certain products, with some preferring simpler options like caffeine-based products.

PP405 is being discussed as a potential hair loss treatment, possibly more effective than minoxidil. There are concerns about its effectiveness and product contamination, but some users report early signs of hair regrowth.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

Creating a topical solution combining finasteride and stemoxydine to treat hair loss, and the discussion of whether 15mg of finasteride would be sufficient for 60ml solvent.

OP used HIMS hybrid tablets containing 1.1mg finasteride, 3mg minoxidil, and 2.5mg biotin, showing significant hair regrowth after initial shedding. OP experienced no side effects and plans to continue treatment.

The conversation discusses concerns about starting topical finasteride due to high estradiol levels and the potential risk of gynecomastia. Suggestions include using ultrasensitive estradiol tests and considering aromatase inhibitors like zinc, ZMA, or DIM supplements.

The user reported using 1.2 mg finasteride and 3 mg minoxidil, experiencing initial shedding and increased hair growth on knuckles, arms, and forehead. They did not notice any significant side effects.

PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.

PP405 may encourage earlier hair growth and slightly increase visible hair count but does not reverse hair follicle miniaturization in male pattern baldness. It does not address damage to the dermal papilla or broken Wnt signaling.

Switching from powdered dutasteride to softgel significantly reduced DHT levels, suggesting softgels are more effective due to better bioavailability. Users discuss the ineffectiveness of compounded forms and emphasize the importance of proper formulation for absorption.

The conversation discusses whether using 0.1% topical finasteride alongside 0.5 mg oral finasteride is excessive, with suggestions to choose either oral or topical treatment. The user also uses 5% minoxidil and mentions concerns about alcohol-based solutions due to seborrheic dermatitis.

A user is concerned that finasteride isn't working for their hair loss, questioning if it's due to male pattern baldness or low iron levels. They are advised to take finasteride daily and get blood work done.

The conversation discusses the cost and insurance coverage of a comprehensive hormone and DHT blood panel for hair loss, with a focus on finasteride treatment. The user seeks a cheaper alternative to a $700 panel recommended in a video.

The conversation is about finding a cheaper source for RU58841, with a suggestion to use Chemyo. One user suggests that RU58841 may not be necessary.

Kirkland Minoxidil typically contains 50-60% propylene glycol. Users suggest adjusting the percentage for sensitive skin.

PP405 is being discussed as a potential treatment for hair loss, with uncertainty about its effectiveness compared to existing treatments like finasteride, dutasteride, and minoxidil. There is cautious optimism, but its impact on hair transplants remains unclear.

The user is experiencing an allergic reaction to propylene glycol in Kirkland minoxidil and is considering switching to a foam version or a low-PG minoxidil solution. They are also contemplating oral minoxidil but are concerned about its long-term safety.

The conversation discusses the effectiveness of using finasteride alone versus combining it with minoxidil, ketoconazole, and microneedling for hair loss treatment. It also touches on the affordability and accessibility of hair transplants, with differing opinions on the financial feasibility of such procedures.

The user is on Finasteride for hair loss, taking 0.5mg daily, and plans to reduce the dose to 0.25mg while making lifestyle changes to lower prolactin, SHGB, and cortisol. They will retest in 90 days to assess progress and are open to advice.

A user is using a pharmacy-compounded topical treatment for hair loss containing minoxidil, finasteride, azelaic acid, caffeine, and an oil blend including argan, jojoba, castor, rosemary, tea tree, and nettle oils. They are questioning if the oil blend improves absorption of the active ingredients compared to a simple alcohol/propylene glycol solution.

Genetic factors, enzyme activity, and DHT sensitivity affect individual responses to hair loss treatments like finasteride, minoxidil, and dutasteride. Starting treatments early can slow hair loss, but results vary among individuals.

PP405 is in a phase 3 trial for hair loss treatment, with the study expected to run until June 2028. Minoxidil and finasteride remain key treatments, with hopes for PP405 to offer a new mechanism of action.

The conversation discusses the effects of B5 (Pantothenic acid), B7 (Biotin), and B12 on hair loss. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

OP noticed an increase in DHT levels after 5 months of using finasteride and is unsure if the drug is effective or if other factors like stress or vitamins are influencing the results. Users suggest testing the medication for authenticity, consulting a doctor, and possibly trying a different brand or dosage.

PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.

Vitamin D tests like D2, D3, and 25-hydroxyvitamin D are discussed before starting hair treatment. Vitamin D can be obtained from food, but overdose has side effects.